Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial

Bourlière, 2011, Chronic hepatitis C: treatments of the future, Clin Res Hepatol Gastroenterol, 35, S84, 10.1016/S2210-7401(11)70013-4 Welsch, 2012, New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives, Gut, 61, i36, 10.1136/gutjnl-2012-302144 Jazwinski, 2011, Direct-acting antiviral medications for chronic hepatitis C virus infection, Gastroenterol Hepatol (N Y), 7, 154 Ghany, 2011, An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver diseases, Hepatology, 2011, 1144 McCown, 2008, The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors, Antimicrob Agents Chemother, 52, 1604, 10.1128/AAC.01317-07 Eldrup, 2004, Structure-activity relationship of heterobase-modified 2′-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication, J Med Chem, 47, 5284, 10.1021/jm040068f Clark, 2006, Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication, Bioorg Med Chem Lett, 16, 1712, 10.1016/j.bmcl.2005.12.002 Sofia, 2010, Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus, J Med Chem, 53, 7202, 10.1021/jm100863x Lawitz E, Rodriguez-Torres M, Denning JM, Albanis E, Cornpropst M, Berrey MM, et al. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Antimicrob Agents Chemother, in press. Medical dictionary for regulatory activities. Available at: http://www.meddramsso.com. Copegus® (ribavirin), Roche, Basel Switzerland. Package Insert; 2011. Pegasys® (peginterferon alfa-2a), Roche, Basel Switzerland. Package Insert, 2011.